Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Immutep LimitedNASDAQ: IMMP

Change in Working Capital · Q2 FY2026 · quarter ended Dec 2025

Change in working capital outflow grows to A$0

Q2 FY2026 change in working capital was A$0, compared with A$0 a year earlier. Over 3 fiscal years it compounded at +76.2% a year.

Context

  • Change in working capital amounted to 169.4% of revenue in FY2025, up 79.4 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
-A$8.54M-347.1% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-347.1%——
3-year CAGR+76.2%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

AUD · from the cash flow

Latest · FY2025
(8.54M) AUD
Year-over-year change
-347.1%

Change in Working Capital vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -347.1% is the 9th highest of 11, against a peer median of -30.8%.
  • Change in working capital amounts to 169.4% of revenue for IMMP, versus a peer median of 78.0%.
IMMP Competitors
Change in Working Capital for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EDITEditas Medicine, Inc.LTM Mar 2026$50.69M USD-411.7%—131.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$15.79M USD+1014.2%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$14.08M USD+115.1%-24.4%245.3%
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
IMMPImmutep LimitedFY2025A$8.54M AUD-347.1%+76.2%169.4%
CABACabaletta Bio, Inc.LTM Mar 2026$6.7M USD-348.8%-55.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$2.34M USD+115.1%+11.0%1.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.52M USD-58.9%-24.9%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$531K USD-62.5%——
CADLCandel Therapeutics, Inc.LTM Mar 2026$447K USD+120.2%+213.8%—
MREOMereo BioPharma Group plcLTM Mar 2026$299.66K USD-178.4%+10.9%59.9%
Peer median (excluding IMMP) —-30.8%+10.9%78.0%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Depreciation & Amortization2.07M2.06M2.06M2.26M2.39M
Deferred Income Tax(7.29M)0(4.99M)00
Stock-Based Compensation1.7M1.49M2M1.8M1.16M
Change in Working Capital(1.99M)(1.56M)764.6K3.46M(8.54M)
Accounts Receivables(2.83M)(2.25M)(1.61M)601.77K(2.52M)
Inventory0813.92K000
Accounts Payables1.38M1.44M3.27M00
Other Working Capital(543.42K)(1.56M)(900.11K)2.86M(6.02M)
Other Non-Cash Items17.77M(8.04K)4.17M379.87K4.37M
Operating Cash Flow(17.64M)(30.23M)(35.88M)(34.82M)(62.05M)
Capital Expenditures(15.6K)(22.91K)(47K)(932.37K)(45.77K)
Acquisitions (Net)00000
Purchases of Investments000(20.09M)0
Sales of Investments00000
Other Investing Activities0016K(903.15K)(38.49M)
Investing Cash Flow(15.6K)(22.91K)(31K)(21.02M)(38.53M)
Debt Repayment(214.38K)(222.54K)(211.97K)(226.49K)(270.67K)
Common Stock Issued43.31M52.98M80.08M100.24M(164.79K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.59M(2.43M)(3.83M)(4.83M)(254.46K)
Financing Cash Flow52.68M50.33M76.04M95.18M(525.12K)
Effect of Forex Changes(752.84K)(671.04K)3.3M(967.73K)6.73M
Net Change in Cash34.27M19.4M43.42M38.37M(94.38M)
Free Cash Flow(17.66M)(30.25M)(35.93M)(35.75M)(62.1M)

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.